Heparin-induced thrombocytopenia (HIT) is a life-threatening disorder that follows exposure to unfractionated heparin or (less commonly) low-molecular-weight heparin (LMWH). Patients classically present with a low platelet count (< 150,000 cells/mm³) or a relative decrease of 50% or more from baseline, although the fall may be less (e.g., 30%–40%) in some patients. Thrombotic complications develop in approximately 20%–50% of patients.

HIT is caused by antibodies against complexes of platelet factor 4 and heparin. These antibodies are present in nearly all patients who receive a clinical diagnosis of the disorder and are also known to cause disease in animals. However, they are also present in many patients who have been exposed to heparin in various clinical settings but who do not develop clinical manifestations. It is uncertain why complications occur in some patients but not in others. We present a 73-year-old man who developed thrombocytopenia after starting LMWH and who has newly diagnosed adenocarcinoma of the lungs with extensive arterial and venous thrombosis and a negative serology for HIT.

**Case presentation**

A 73-year-old man presented to the emergency department after waking up in the morning with right-sided vague weakness and an inability to get out of bed. He had a history of right parietal stroke 1 month before the current presentation, when he was diagnosed with an aortic arch atheroma and started on warfarin. (At that time, CT scan of the head showed a right posterior temporoparietal lobe infarct in the posterior or right middle cerebral artery distribution, and MRI of the brain and magnetic resonance angiography showed acute or subacute infarction in the distribution of the posterior division of the right middle cerebral artery, likely embolic, and tiny acute infarctions in the left frontal lobe.) This patient had been admitted 5 days prior to the current presentation for right lower extremity deep vein thrombosis (DVT) and was discharged after being prescribed enoxaparin (60 mg subcutaneously every 12 hours) and warfarin as per international normalized ratio (INR) daily.

Also included in the medical history was supraventricular tachycardia status post ablation, non–ST elevation myocardial infarction (NSTEMI), hypertension, hyperlipidemia, and macular degeneration. He had no surgical history. The patient had a family history of coronary artery disease. He had an extensive smoking history up until the day of admission. His medications on admission included atorvastatin (Lipitor; 20 mg daily), warfarin daily as per INR, enoxaparin (60 mg subcutaneously every 12 hours), amiodapine (5 mg daily), and aspirin (81 mg daily).

Pertinent initial laboratory results on admission were as follows: hemoglobin, 12.9 g/dL; white blood cell count, 8.6 × 10⁹/L; platelet count, 183,000 cells/mm³; INR, 1.2; and initial troponin level, negative. His admission chest x-ray showed a 4.5 cm × 5.5 cm lobulated density in the right hilum, suspicious for a hilar or subcarinal mass. Initial CT of the head on admission showed no evidence of acute
transcortical infarction and no definite evidence of acute intracranial hemorrhage but did show interval evolution of the right middle cerebral artery and left watershed distribution infarctions, with a probable small region of laminar necrosis in the right parietal lobe.

**Clinical course**

The patient was initially thought to have had a transient ischemic attack causing aphasia, confusion, and right-sided weakness. He was started on therapeutic anticoagulation with dalteparin (Fragmin; 12,000 U subcutaneously daily), and enoxaparin was discontinued. The following day, his platelet count was 86,000 cells/mm³, down from an admission platelet count of 183,000 cells/mm³.

A subsequent MRI of the brain showed a new hemorrhagic area in the right parietal infarct (Figure 1). The decision was made to stop anticoagulation, even though he had an embolic source from his aortic arch atheroma and lower extremity DVT.

The patient then underwent inferior vena cava (IVC) filter placement to prevent pulmonary thromboembolism and was transferred to the medical service due to low platelet count and an episode of nine beats of ventricular tachycardia. Subsequently, his troponin level was found to be elevated > 12 ng/mL, without significant electrocardiographic changes. He was diagnosed as having NSTEMI. Given his conversion from an ischemic to hemorrhagic CNS infarct and decrease in platelet count after LMWH exposure, HIT became a concern, and both anticoagulation and antiplatelet agents were held. The patient began to have worsening right lower extremity pain and left upper quadrant abdominal pain.

A CT scan of the thorax showed multifocal right hilar adenopathy suspicious for malignancy, either metastatic or representing a central lung carcinoma. It also showed nonocclusive segmental and possibly subsegmental pulmonary emboli in the right lower and middle lobes, as well as hypodense areas in the spleen, suggestive of areas of splenic infarction. Echocardiography showed an ejection fraction of 60%–70%, diastolic dysfunction, mildly elevated pulmonary artery pressure, and no evidence of patent foramen ovale. A cardiac stress test showed no reversible defects and an ejection fraction of 63%.

Risk of further bleeding into the brain was thought to be too great to initiate anticoagulation despite the CT thorax findings. The neurologist recommended waiting 2 weeks post hemorrhagic infarction before beginning anticoagulation. Antiphospholipid antibody syndrome was ruled out, with a negative lupus anticoagulant and anticardiolipin antibody. Also, negative blood cultures, normal fibrinogen levels, and normal haptoglobin levels ruled out disseminated intravascular coagulation. D-dimer was elevated but nonspecific, secondary to malignancy and multiple infarcts. He was started on aspirin (81 mg daily) 9 days after admission.

The patient had a repeat CT scan of the thorax and CT scan of the abdomen and pelvis due to continued abdominal pain. The CT scans showed multiple subsegmental pulmonary emboli, greatest in the right lower lobe, some of which were new since the prior study (Figure 2); continued evidence of multifocal splenic infarction (Figure 3); and multiple right and left kidney infarcts (Figure 3).

The patient then underwent endobronchial ultrasound (EBUS)-guided biopsy of his right hilar adenopathy to confirm the diagnosis of suspected malignancy. After the procedure, he developed right upper quadrant pleuritic pain with a low-grade fever. A repeat CT scan of the thorax showed a marked increase in the extent of the
right lower lobe pulmonary emboli, with a new small embolus noted in the anterior segment of the right upper lobe. There was a thrombus inferior to the IVC filter, with probable mild extension of a thrombus superior to the filter as well, and again multiple splenic and bilateral renal infarcts.

With progression of thrombosis and now post EBUS, anticoagulation was initiated with argatroban and warfarin. His D-dimer was followed daily and remained high, despite therapeutic anticoagulation with warfarin. Given the persistently elevated D-dimer, the hematologist recommended discontinuing warfarin and starting fondaparinux (Arixtra) subcutaneously. His platelet count improved to a range of 156,000 cells/mm³ to 181,000 cells/mm³, even before the initiation of chemotherapy.

**Follow-up**

HIT was suspected clinically by classic drop in platelet count but was negative on enzyme-linked immunosorbent assay (ELISA) and serotonin release assay (SRA). The patient has been maintained on fondaparinux for anticoagulation, avoiding heparin. Factor V Leiden and lupus anticoagulant were negative.

Fondaparinux was discontinued after 3 months, and the patient presented again with swelling of his right lower extremity. Ultrasonography of the right lower extremity demonstrated an occlusive thrombus in the peripheral portion of the right femoral vein and throughout the right peroneal vein. The patient was restarted on fondaparinux (7.5 mg subcutaneously daily). During this follow-up, his platelet count ranged from 134,000 cells/mm³ to 193,000 cells/mm³.

Regarding management of non-small cell lung carcinoma of the left upper lobe (stains positive for TTF-1 [thyroid transcription factor-1], CK7, and CK20; weakly positive for CK5/6; and negative for P63) with metastasis to bone and adrenal glands, he received 4 cycles of paclitaxel/carboplatin, with improved disease. A repeat CT of the chest, abdomen, and pelvis after chemotherapy showed improvement in mediastinal and hilar lymphadenopathy, resolution of extensive right lower lobe pulmonary consolidation, resolution of right-sided effusion, and no evidence of metastatic malignancy in the abdomen or pelvis and no osseous metastasis.

He was started on maintenance therapy with pemetrexed (Alimta), which was continued for 4 months, until repeat CT revealed progressive disease. He then received 4 cycles of vinorelbine. He had progression-free survival of 7 months from first-line chemotherapy and stable disease for 7 months after 4 cycles of vinorelbine.

**Discussion**

In summary, we have a 73-year-old man admitted with a hemorrhagic infarct, NSTEMI, and recently diagnosed right lower extremity DVT with a decreasing platelet count in the setting of LMWH. Throughout the hospital course, he had worsening hemorrhagic infarcts, preventing proper anticoagulation for his progressive thromboembolic events in the lungs, spleen, kidneys, and legs. Incidentally, he was also found to have a mass on a chest x-ray, later identified by biopsy as adenocarcinoma.

Given that the 4T scoring system for HIT showed a high probability with 8 points—identified by a platelet count fall > 50%, a platelet nadir > 20,000 cells/mm³, clear onset between days 5 and 14 with exposure to heparin/LMWH, new thrombosis, and no apparent cause of thrombocytopenia—suspicion for HIT remained high. Both functional and immunologic assays were negative for HIT, when repeated 2 weeks apart. The assays for laboratory diagnosis of HIT are immunologic, done by ELISA with a sensitivity of > 95% and a specificity of 50%–89%, and functional, done by SRA with a sensitivity > 90% and a specificity > 90%. As neither assay is 100% sensitive and specific, we still had a high clinical suspicion for HIT.

The HIT diagnostics in the presence of other comorbid states that may also induce thrombocytopenia represent a specific clinical problem.
Despite increasing awareness of the clinical features of HIT, laboratory detection of the pathogenic HIT antibodies remains central to diagnosis. This is because thrombocytopenia during heparin anticoagulation does not necessarily indicate HIT. Indeed, several other disorders complicated by thrombosis and thrombocytopenia during or shortly following heparin treatment strongly resemble HIT. These “pseudo-HIT” disorders (eg, cancer, sepsis, disseminated intravascular coagulation, pulmonary embolism, antiphospholipid syndrome) can reliably be distinguished from HIT by negative results using sensitive tests for HIT antibodies.

Thrombosis is strongly associated with HIT, with an incidence of 50%–67%. The most common complication of HIT is venous thrombosis (DVT being the most frequent, followed by pulmonary embolism). Arterial thrombosis commonly presents as limb ischemia followed by cerebral vascular accident and myocardial infarction. Our patient had DVT followed by NSTEMI, cerebral vascular accident and myo-cardial infarction. We considered this with our patient; however, a literature review showed no cases of Trousseau’s syndrome associated with heparin-induced thrombocytopenia: a prospective study. Circulation 1999;99:73–80.


References